Orphazyme CFO: 2021 will be the decisive year

Orphazyme's CFO and and interim CEO Anders Vadsholt is vocal that 2021 can be an important year for the biotech company.

Orphazyme Chief Financial Officer and interim CEO Anders Vadsholt | Photo: Orphazyme / PR

"This will be the decisive year."

So says Orphazyme Chief Financial Officer and interim CEO Anders Vadsholt, when asked to explain how important this current year is to the Danish biotech company.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs